Weed Inc (OTCMKTS:BUDZ) is staging a comeback after ferocious sell-off that saw it shed a substantial amount of market value in 2018. A 60% rally has helped pull the stock from all-time lows, as sentiments in the market continue to show signs of improvement.
Weed Inc. Price Analysis
The recent spark in the market comes on the company confirming the completion of a proprietary cannabis Genomics Pilot study. In a press release, the company says, its scientists were able to design, test and refine standard operating procedures for efficient DNA isolation and sequencing of Cannabis genomes.
Reports that the company has expanded its footprint in Israel and Australia is another development that continues to strengthen the stock’s sentiments among investors. While the stock is showing signs of trading higher, it still faces an uphill task to recoup losses accrued last year.
The stock is down by more than 80% for the year and in dire need of new groundbreaking catalysts to strengthen the emerging uptrend. After the recent spike higher, the stock needs to rally and stabilize above the $2 a share level, if it is to have any chance of continuing to climb higher.
Above the $2 a share level, bulls could come in and trade the stock as a bounce-back play from current lows. Below the $2 a share level, the stock remains vulnerable to further drops given that short sellers remain in firm control. For the stock to turn bullish, it will have to rally and stabilize above the $6 a share level.
What Does Weed Inc Do?
Weed Inc. casts itself as a multi-faceted vertically integrated world-class Cannabis organization. Through its subsidiaries, the company develops cannabis-derived compounds for the treatment of various diseases.
Genomics Pilot Study
Weed Inc. is the subject of renewed investor interest on the announcement of positive cannabis genomics pilot study results. The results mark the first phase of the company’s 5-year genomic research study. Study findings pave the way for the company to extend the development of a comprehensive genomic resource for the identification of cannabis plants.
Plans are already underway to carry out a second phase that will allow Weed Inc. to include the development of a reference genome and transcriptase. The ultimate goal is to come up with a database for the Comprehensive Molecular Breeding Platform.
“Completion of these tasks will allow WEED, Inc. to create a Universal Genotyping Assay (UGA) for Cannabis cultivars to genetically identify and classify cultivars in a low-cost, high throughput manner. The UGA will be a vital component in the decision-making process for robotic molecular breeding systems,” said Dr. Kamil Khanipov of Industrial Metagenomics.
Strengthening Intellectual Property Portfolio
Separately, in the last quarter of last year, the company completed the acquisition of WEED (R) trademarks. The acquisition paves the way for the company to acquire intellectual property relevant to the industry as it seeks to expand its brand division into a variety of goods and services.
The company has already confirmed plans to expand its product portfolio to include goods and services that includes cosmetics and natural agricultural products.
“We are hopeful that such actions to protect existing rights and acquire future intellectual property rights will fortify WEED, Inc.’s position as a leader in the cannabis industry, creating shareholder value above and beyond the value created by the company’s core business,” comments WEED, Inc. President/CEO Glenn E. Martin.
A push to expand intellectual property portfolio as well as product line followed the expansion of the company’s footprint into Israel and Australia. In Israel, Weed Inc. has already established WEED Israel. The subsidiary is to team up with hospitals universities as well as charitable organizations with the aim of educating people on the need to shop opioid dependency by turning to cannabis treatments. Plans are also underway to work with the Ministry of Health with the aim of growing cannabis export markets.
After a rollercoaster 2018, Weed Inc. has started showing signs of bottoming out. A high turnover in traded shares attests to renewed investor interest in the stock, on the company reiterating its long-term growth prospects.
The company has already made impressive strides in strengthening its intellectual portfolio and product line, key to generating long-term value. Given the underperformance of last year, BUDZ could be a big winner in 2019.
We will be updating our subscribers as soon as we know more. For the latest updates on BUDZ, sign up below!
Disclosure: We have no position in BUDZ and have not been compensated for this article.